Filing Details

Accession Number:
0000899243-16-016850
Form Type:
4
Zero Holdings:
No
Publication Time:
2016-03-29 19:08:52
Reporting Period:
2016-03-28
Filing Date:
2016-03-29
Accepted Time:
2016-03-29 19:08:52
SEC Url:
Form 4 Filing
Issuer
Cik Name Symbol Sector (SIC) IRS No
1609809 Seres Therapeutics Inc. MCRB Pharmaceutical Preparations (2834) 274326290
Insiders
Cik Name Reported Address Insider Title Director Officer Large Shareholder Other
1643734 D. Eric Shaff C/O Seres Therapeutics, Inc.
215 First Street
Cambridge MA 02142
Cfo And Evp No Yes No No
Reported Non-Derivative Transactions
Sec. Name Acquisiton - Disposition Date Amount Price Remaning Holdings Equity Swap Involved Form Type Code Nature of Ownership Explanation
Common Stock Acquisiton 2016-03-28 5,473 $7.79 5,473 No 4 M Direct
Common Stock Disposition 2016-03-28 5,473 $24.07 0 No 4 S Direct
Equity Swap Involved Form Type Code Nature of Ownership Explanation
No 4 M Direct
No 4 S Direct
Reported Derivative Transactions
Sec. Name Sec. Type Acquisiton - Disposition Date Amount Price Amount - 2 Price - 2
Common Stock Stock Option (right to buy) Disposition 2016-03-28 5,473 $0.00 5,473 $7.79
Remaning Holdings Exercise Date Expiration Date Equity Swap Involved Transaction Form Type Transaction Code Nature of Ownership
257,219 2024-12-08 No 4 M Direct
Footnotes
  1. The sale reported in the Form 4 was effected pursuant to a Rule 10b5 1 trading plan adopted by the Reporting Person.
  2. The price reported is a weighted average price. These shares were sold in multiple transactions at per share prices ranging from $24.00 to $24.21. The Reporting Person undertakes to provide upon request to the SEC staff, the Issuer, or any stockholder of the Issuer, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
  3. The option vested as to 25% of the shares subject to the option on November 17, 2015, and has vested or will vest as to an additional 6.25% of the total number of shares subject to the option upon the completion of each three consecutive months of service thereafter.